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Interleukin (IL)-4 is known to be the most potent cytokine that can initiate Th2 cell 
differentiation. Paradoxically, IL-4 instructs dendritic cells (DCs) to promote Th1 cell 
differentiation. We investigated the mechanisms by which IL-4 directs CD4 T cells toward 
the Th1 cell lineage. Our study demonstrates that the IL-4–mediated induction of Th1 cell 
differentiation requires IL-10 production by DCs. IL-4 treatment of DCs in the presence of 
lipopolysaccharide or CpG resulted in decreased production of IL-10, which was accompanied 
by enhanced IL-12 production. In IL-10–deficient DCs, the level of IL-12 was greatly 
elevated and, more importantly, the ability of IL-4 to up-regulate IL-12 was abrogated. 
Interestingly, IL-4 inhibited IL-10 production by DCs but not by B cells. The down-regulation 
of IL-10 gene expression by IL-4 depended on Stat6 and was at least partly caused by 
decreased histone acetylation of the IL-10 promoter. These data indicate that IL-4 plays a 
key role in inducing Th1 cell differentiation by instructing DCs to produce less IL-10.
 
DCs, specialized APCs derived from BM pre-
cursors, carry out important functions during
both innate and adaptive immune responses (1,
2). On exposure to stimuli such as infectious
agents, immature DCs located in peripheral
tissues capture the antigen and migrate to sec-
ondary lymphoid organs during maturation
(3). Mature DCs express high levels of MHC
class II and costimulatory molecules, and they
are potent professional APCs to prime naive
CD4 T cells (4). Activated DCs secrete both
inflammatory and antiinflammatory cytokines,
which regulates the immune response. Depend-
ing on the pattern of cytokines secreted during
the interaction between DCs and T cells, the
immune response can polarize toward either a
cellular or a humoral response mediated by
Th1 or Th2 cells, respectively (5, 6).
IL-4 is a pleiotropic immunomodulatory
cytokine produced by Th2 lymphocytes, mast
cells, and eosinophils (7). IL-4 is the key cy-
tokine for generating Th2 effector cells from
naive CD4 T cells (8). In addition, IL-4 activates
B cells but inhibits macrophage activation,
which results in humoral immunity (9, 10).
Although IL-4, together with GM-CSF, is
commonly used to differentiate DCs from BM
precursors, the effect of IL-4 on DC matura-
tion remains largely unknown. Studies have
demonstrated that IL-4 enhances the production
of IL-12p70 by DCs (11, 12). Because IL-12 is a
potent cytokine directing Th1 cell differentia-
tion (13), IL-4 is suggested to have a positive
role for Th1 cell differentiation via DCs. In-
deed, it was reported that IL-4 can instruct
DCs to promote the Th1 response, which de-
pends on IL-12 (14). However, it is unclear
how IL-4 induces IL-12 production in DCs
that leads to Th1 cell differentiation. A possible
mediator for this process is IL-10 because IL-10
inhibits IL-12 production by DCs (15). How-
ever, it remains unknown whether IL-10 is re-
sponsible for IL-4–mediated induction of the
Th1 response.
We investigated the molecular mechanisms
by which IL-4 directs Th1 cell differentiation.
Our data showed that IL-4 up-regulates IL-12
while inhibiting IL-10 production by DCs,
but not by B cells. The inhibition of IL-10 by
IL-4 appears necessary for the induction of
Th1 cell differentiation because the ability of
IL-4 to induce IL-12 was lost in IL-10–deficient
DCs. IL-4 inhibits IL-10 promoter activity,
which depends on Stat6 and involves histone
deacetylation of the IL-10 promoter. As a result,
IL-4 plays a key role for Th1 cell differentia-
tion by inhibiting IL-10 gene expression to
up-regulate IL-12 production by DCs.
 
RESULTS AND DISCUSSION
IL-4 inhibits IL-10 while enhancing IL-12p70 
production by BM-derived DCs (BM-DCs)
 
To examine the effects of IL-4 on DC matura-
tion, we cultured BM cells with GM-CSF for
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5 d, followed by stimulation with LPS in the presence or ab-
sence of IL-4 for 2 d. IL-4–treated DCs had similar popula-
tions of CD11c
 
 
 
CD11b
 
 
 
CD8
 
 
 
 
 
B220
 
 
 
 DCs and expressed
comparable levels of MHC II and the costimulatory mole-
cules CD40, CD80, and CD86 as controls (unpublished
data). When cytokine production was examined, DCs stim-
ulated in the presence of IL-4 produced less IL-10 but more
IL-12p70 (Fig. 1 A). IL-6 and TNF-
 
 
 
 levels were not al-
tered by IL-4 (Fig. 1 A). IL-4 treatment showed a similar ef-
fect on cytokine production from DCs stimulated by CpG
(unpublished data), indicating that culture with IL-4 affects
stimulation by both TLR4 and TLR9 ligands (16). Thus, IL-
4–treated BM-DCs produce less IL-10 and more IL-12p70.
To determine whether the changes in protein levels cor-
relate with their mRNA levels, BM-DCs were stimulated by
LPS with or without IL-4 for 24 h, and the mRNA levels of
IL-10 and IL-12 were measured using quantitative real-time
RT-PCR (qRT-PCR). As shown in Fig. 1 B, IL-4 had lit-
tle effect on the basal level, but considerably inhibited LPS-
inducible IL-10 gene expression. In addition, the IL-12p35,
but not the IL-12p40, mRNA level was enhanced by IL-4,
which is consistent with a previous study (11). IL-6 expres-
sion was comparable with or without IL-4. Therefore, IL-4
reduces IL-10 and induces IL-12 production by regulating
IL-10 and IL-12p35 mRNA expression.
 
Induction of Th1 cell differentiation by IL-4–treated DCs is 
IL-10 dependent
 
IL-10 is known to inhibit IL-12 expression (15). Therefore,
it is possible that the induction of IL-12 by IL-4 is caused by
the reduction of IL-10 production. To test this, we exam-
ined cytokine production by 
 
IL-10
 
 
 
/
 
 
 
 DCs. 
 
IL-10
 
 
 
/
 
 
 
 BM-
DCs secreted more IL-12 and expressed higher IL-12p35
mRNA than control DCs on LPS stimulation (Fig. 2, A and
B). More importantly, the effect of IL-4 on IL-12 produc-
tion and IL-12p35 mRNA expression was abolished in 
 
IL-
10
 
 
 
/
 
 
 
 DCs (Fig. 2, A and B). These data indicate that the
up-regulation of IL-12 by IL-4 correlates with decreased IL-
10 levels.
To confirm the role of IL-10 in IL-4–mediated Th1 cell
differentiation, we tested the ability of DCs to differentiate
CD4 T cells. Total BM cells were prepared from BALB/c
WT and 
 
IL-10
 
 
 
/
 
 
 
 mice and cultured for 5 d in the presence
of GM-CSF to generate BM-DCs. BM-DCs at day 5 were
stimulated for 6 h with LPS alone or LPS with IL-4 and
washed extensively to eliminate cytokines in the culture.
CD4
 
 
 
 T cells from DO11.10 mice were enriched and dif-
Figure 1. IL-4 inhibits IL-10 while enhancing IL-12 expression in 
BM-DCs. (A) BM-DCs from C57BL/6 mice were stimulated by LPS with or 
without IL-4 for 2 d. ELISA was performed to measure IL-6, IL-10, IL-12p70, 
and TNF-  production. (B) BM-DCs were stimulated for 24 h as indicated. 
qRT-PCR was performed to assess the amount of mRNA for IL-10, IL-6, 
IL-12p35, and IL-12p40. The relative mRNA levels were normalized to the 
GAPDH gene. Data are means   SE of at least three independent experiments.
Figure 2. IL-4 up-regulates IL-12 and promotes Th1 cell differen-
tiation by inhibiting IL-10. (A) BM-DCs were prepared from BALB/c WT 
and IL-10 /  mice and stimulated with LPS alone or LPS with IL-4 for 1 d. 
ELISA was performed to detect IL-10 and IL-12p70 production. (B) BM-DCs 
from BALB/c WT and IL-10 /  mice were activated for 6 h with the indi-
cated stimuli. IL-12p35 mRNA expression was measured by qRT-PCR. 
(C) BM-DCs were generated from BALB/c WT and IL-10 /  mice and 
treated with LPS alone or LPS with IL-4 for 6 h. 2   104 BM-DCs were then 
washed and added to 2   105 CD4  T cells enriched from splenocytes of 
DO11.10 TCR-transgenic mice together with 0.01 M OVA peptide and 
50 U/ml rIL-2. 5 d later, CD4 T cells were restimulated overnight with 
plate-bound anti-CD3 antibody. Supernatants were collected to measure 
IL-4 and IFN-  production by ELISA. Data are means   SE of three inde-
pendent experiments. 
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ferentiated by providing OVA peptides as antigens and stim-
ulated BM-DCs as APCs. 5 d later, live cells were restimu-
lated overnight by anti-CD3 antibody, and IL-4 and IFN-
 
 
 
production was measured.
Two interesting observations emerged. First, CD4 T
cells primed by IL-4–treated BM-DCs from WT mice pro-
duced more IFN-
 
 
 
 and less IL-4 than cells primed by DCs
treated without IL-4 (Fig. 2 C). In contrast, this effect of IL-4
was not observed when DCs from 
 
IL-10
 
 
 
/
 
 
 
 mice were used
as APCs to prime CD4 T cells. Second, 
 
IL-10
 
 
 
/
 
 
 
 DCs were
more potent to direct Th1 cell differentiation than WT
DCs. This finding may be caused by the elevated IL-12 pro-
duction by 
 
IL-10
 
 
 
/
 
 
 
 DCs, as shown in Fig. 2 A.
 
IL-4 inhibits IL-10 production by DCs but not by B cells
 
IL-10 is produced not only by DCs but also by other APCs,
including B cells (17). In addition, IL-4 activates B cells and
induces Ig isotype switching (7). Therefore, we asked
whether IL-10 production by B cells is also suppressed by
IL-4. Splenic B cells were purified and cultured in the pres-
ence of LPS alone or LPS with IL-4 for 2 d. As a control, we
also stimulated purified splenic DCs with LPS or CpG in the
presence or absence of IL-4. Consistent with BM-DCs,
splenic DCs produced less IL-10 if IL-4 was added to the
culture (Fig. 3 A). On the contrary, IL-4 did not inhibit IL-
10 production by B cells. Rather, the IL-10 level was in-
creased in the presence of IL-4 (Fig. 3 B). Thus, the inhibi-
tory effect of IL-4 on IL-10 production is specific for DCs
and the molecular mechanisms governing IL-10 expression
must be distinct between DCs and B cells.
 
Stat6 is required for IL-4–mediated inhibition of IL-10
 
To further ascertain how IL-4 regulates IL-10 gene expres-
sion in DCs, we tested the role of Stat6, which is a primary
molecule mediating the IL-4 signal (18, 19). 
 
Stat6
 
 
 
/
 
 
 
 BM-
DCs produced an equivalent level of IL-10 protein, as well
as mRNA, in response to LPS (Fig. 4, A and B). However,
unlike DCs from the control mice, IL-4 was unable to in-
hibit IL-10 expression in 
 
Stat6
 
 
 
/
 
 
 
 DCs (Fig. 4, A and B).
Therefore, Stat6 is required for the inhibitory effect of IL-4
in DCs.
 
IL-4 down-regulates IL-10 promoter activity by decreasing 
histone acetylation
 
There are at least two possibilities that can explain the de-
crease of IL-10 mRNA by IL-4: decreased mRNA stability
or transcription. To distinguish these possibilities, we first
measured IL-10 mRNA half-lives and found that there was
no difference in IL-10 mRNA half-life with and without
IL-4 (Fig. 5 A). We next examined IL-10 promoter activity
in the DC cell line DC2.4 using a transient transfection
method. DC2.4 cells were transfected with the luciferase re-
porter driven by the IL-10 promoter, followed by stimula-
tion with LPS in the presence or absence of IL-4. Luciferase
activity was enhanced by LPS but not by LPS together with
IL-4, indicating that IL-4 down-regulates IL-10 promoter
activity in DCs (Fig. 5 B).
To confirm that IL-4 has a similar effect on the endoge-
nous IL-10 promoter, we examined the histone acetylation sta-
tus of the IL-10 promoter by chromatin immunoprecipitation
(ChIP) assay. As shown in Fig. 5 C, histone acetylation of the
IL-10 promoter was enhanced in LPS-treated BM-DCs. The
induction of histone acetylation by LPS was compromised by
IL-4 in WT DCs, but not in 
 
Stat6
 
 
 
/
 
 
 
 DCs (Fig. 5 C).
IL-4 inhibits the LPS-inducible, but not the basal, level
of IL-10 expression (Fig. 1 B and Fig. 5 B), suggesting cross
talk between IL-4–induced and LPS-mediated signaling
pathways. Mitogen-activated protein kinase and NF-
 
 
 
B sig-
nals have been demonstrated to be involved in DC activa-
tion and cytokine production (16). However, IL-4 did not
affect LPS-mediated mitogen-activated protein kinase or
NF-
 
 
 
B activation in BM-DCs (unpublished data). This
finding is not surprising because IL-4 did not have a global
inhibitory effect on cytokine production by DCs. It is not
clear how IL-4 down-regulates IL-10 gene expression via
Stat6. We suspect that IL-4–activated Stat6 may compete
with other transcription factors and/or cofactors that are es-
sential for LPS-inducible expression of the IL-10 gene in
DCs. Whatever the mechanisms might be, IL-4–mediated
regulation of IL-10 in DCs could play an important role in
mounting a proper Th response. However, we cannot rule
out the possibility that IL-4 may affect additional DC func-
tions that have not been investigated.
A recent study has demonstrated that IL-4 instructs Th1
responses, which in turn protects mice from 
 
Leishmania
 
 
 
major
Figure 3. IL-4 inhibits IL-10 production by splenic DCs, but not by 
splenic B cells. CD11c  DCs (A) and B220  B cells (B) were enriched from 
the spleen of C57BL/6 mice using magnetic selection and stimulated with 
LPS or CpG in the presence or absence of IL-4, as described in Materials 
and methods. ELISA was performed to detect IL-10 production. Data are 
means   SE of three independent experiments.
Figure 4. IL-4 inhibits IL-10 gene expression in a Stat6-dependent 
manner. BM-DCs from C57BL/6 WT and Stat6 /  mice were stimulated by 
LPS with or without IL-4 for 24 h. ELISA and qRT-PCR were performed to 
detect IL-10 protein (A) and mRNA (B), respectively. Data are means   SE 
of three independent experiments. 
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infections (14). Interestingly, the authors elegantly showed
that the effect of IL-4 in eliciting the Th1 response is limited
to the initial stage of infection, although the mechanisms for
this observation were not provided. Similarly, other studies
also have shown initial Th1 responses during the early stage of
infection with 
 
L. amazonensis
 
 or 
 
Schistosomiasis mansoni
 
 in 
 
IL-
10
 
 
 
/
 
 
 
 mice (20, 21). Despite this early response, parasites per-
sisted in chronic lesions with normal Th2 responses in the ab-
sence of IL-10 (20, 21). We showed that IL-4 inhibits IL-10
production by both splenic and BM-DCs, but not by B cells,
on LPS stimulation (Fig. 3). This suggests that all DCs share
common regulatory mechanisms to produce IL-10. Given the
potency of DCs as APC-activating naive CD4 T cells, the
presence of IL-4 during the initial phase of the immune re-
sponse would favor the generation of Th1 cells. B cells pri-
marily reside in the secondary lymphoid organs, which pre-
vents them from encountering antigens early in the response.
If an infection progresses, B cells would be activated and be
able to present antigens to naive CD4 T cells. In B cells, how-
ever, IL-4 does not inhibit IL-10 production. Instead, IL-4
would help B cells to produce more IL-10 and skew the im-
mune response toward Th2 cells. Therefore, a shift from Th1
to Th2 responses by IL-4 is at least partly caused by a change
in the cell type presenting antigens to T cells.
With this scenario, one would expect to see a dominant
Th1 response in the absence of B cells. Indeed, DCs produced
more IL-12 in the absence of B cells, resulting in Th1 cell devi-
ation (22). This study also showed that B cells regulate the ca-
pacity of DCs to promote IL-4 secretion, further enhancing the
Th2 response. Therefore, there is a negative feedback loop of
cytokine production controlled by different APCs. In addition,
B cell–deficient mice did not show recovery from disease in a
Th1 cell–dependent model of experimental autoimmune en-
cephalomyelitis (23). Experimental autoimmune encephalomy-
elitis recovery was dependent on IL-10 production by B cells.
In the absence of B cells, DCs would be the primary APC-acti-
vating CD4 T cells, generating pathogenic Th1 cells and en-
hancing the severity of the disease. It is likely that the presence
of both DCs and B cells is important to balance Th1 and Th2
cell generation and, moreover, proper temporal regulation of
cytokine production for an effective immune response.
In conclusion, we showed that IL-4 directs DCs to pro-
duce less IL-10, resulting in more IL-12 production to pro-
mote the Th1 response. Therefore, IL-4 has a dual role for
Th cell differentiation, and the type of APCs present during
the initial activation of CD4 T cells appears critical for the
CD4 T cell effector function.
 
MATERIALS AND METHODS
 
Mice and cells.
 
C57BL/6, BALB/c, and IL-10–deficient (
 
IL-10
 
 
 
/
 
 
 
) mice
were purchased from the Jackson Laboratory. 
 
Stat6
 
 
 
/
 
 
 
 mice were as previ-
ously described (18). All mice were maintained under specific pathogen-
free conditions at the Indiana University School of Medicine animal facility.
BM-DCs were prepared as previously described (24). In brief, total BM
cells depleted of T and B cells were cultured for 5 d in RPMI 1640 with 5%
FBS and 10 ng/ml murine rGM-CSF (BD Biosciences). These cells were
considered immature DCs. Immature DCs were replated at 10
 
6
 
 cells/ml and
matured in the presence of 1 
 
 
 
g/ml LPS (
 
Escherichia coli
 
 O55:B5 serotype;
Sigma-Aldrich) or 2 
 
 
 
g/ml CpG (TCCATGACGTTCCTGATGCT)
with or without 10 ng/ml murine rIL-4 (BD Biosciences) for up to 2 d.
Splenic DCs and B cells were isolated by positive selection with anti-
CD11c and anti-B220 magnetic beads (Miltenyi Biotec), respectively. Splenic
DCs were activated for
 
 
 
24 h using the same conditions as BM-DCs. Splenic
B cells were cultured at a density of 10
 
6 
 
cells/ml in RPMI 1640 with 10%
FBS and stimulated for 48 h by 4 
 
 
 
g/ml LPS with or without 5 ng/ml rIL-4.
 
FACS analysis.
 
Abs used for flow cytometry, CD11c (clone HL3),
CD11b (clone M1/70), CD8
 
 
 
 (clone 53–6.7), CD45R (B220; clone RA3-
6B2), CD40 (clone 3/23), CD80 (B7-1; clone 16-10A1), CD86 (B7-2;
clone GL-1), and MHC class II (I-A
 
b
 
; clone AF6-120.1), were obtained
from BD Biosciences. Flow cytometric analysis was performed using FACS-
Calibur and analyzed using CellQuest software (BD Biosciences).
 
ELISA.
 
Cytokine concentrations in the culture supernatants were detected
by ELISA as previously described (25). Purified anti–mouse capture and
biotinylated detection Abs were IL-6 (P5-20F3, MP5-32C11), IL-10,
(JES5-2A5, SXC-1), IL-12p70 (9A5, C17.8), TNF-
 
  
 
(G281-2626, MP6-
XT3), IFN-
 
 
 
 (R4-6A2, XMG1.2), and IL-4 (11B11, BVD6-24G2). All
Abs were obtained from BD Biosciences.
 
qRT-PCR.
 
Total RNA was prepared using Trizol (Invitrogen), and
cDNA was prepared as previously described (26). qRT-PCR was performed
by the comparative threshold cycle (
 
 
 
C
 
T
 
) method and normalized to
GAPDH. The primers used for IL-10, IL-6, and GAPDH were as described
previously (24). The primers used for IL-12p35 were 5
 
 
 
-CCTCAGTTTG-
GCCAGGGTC-3
 
 
 
 and 5
 
 
 
-CAGGTTTCGGGACTGGCTAAG-3
 
  
 
and for
IL-12p40 were 5
 
 
 
-GGAAGCACGGCAGCAGAATA-3
 
 
 
 and 5
 
 
 
-AACT-
TGAGGGAGAAGTAGGAATGG-3
 
 
 
.
Figure 5. IL-4 inhibits LPS-inducible IL-10 gene expression. 
(A) BM-DCs from C57BL/6 mice were stimulated 6 h with LPS alone or LPS 
with IL-4, followed by a 5- g/ml actinomycin D treatment to stop RNA 
synthesis. The remaining IL-10 mRNA levels were measured by qRT-PCR at 
the indicated time points. (B) DC2.4 cells were transfected with the IL-10 
promoter–driven luciferase reporter, stimulated by 2.5  g/ml LPS with or 
without 10 ng/ml IL-4 overnight, and harvested to assess luciferase activ-
ity. Relative luciferase activity was normalized by protein concentrations. 
(C) BM-DCs from C57BL/6 and Stat6 /  mice were stimulated by LPS with 
or without IL-4 for 90 min. ChIP was performed using Abs specific for the 
acetylated histone H4 or normal rabbit serum. Purified DNA fragments 
were amplified using primers specific for the IL-10 or the HPRT promoter, 
as described in Materials and methods. Data are means   SE (A and B) or 
representative (C) of at least three independent experiments. 
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Transient transfections and luciferase assays.
 
DC2.4 cells were main-
tained in RPMI 1640 with 10% FBS, 50 
 
 
 
M 2-ME, 2 mM 
 
L
 
-glutamine, and
100 
 
 
 
g/ml penicillin and streptomycin. 10
 
6
 
 cells were transiently transfected
with the 802- bp IL-10 promoter–driven luciferase reporter plasmid (provided
by M. Tone, University of Pennsylvania, Philadelphia, PA, and H. Waldmann,
University of Oxford, Oxford, UK; reference 27) using the Lipofectamine
Plus reagents (Invitrogen). 4 h after transfection, cells were divided into four
wells and rested 3 h before receiving different treatments overnight. Cell lysates
were prepared and used for luciferase assays as previously described (25). Rela-
tive luciferase activity was normalized by protein concentration.
 
ChIP assay.
 
ChIP assays were performed essentially according to Upstate
Biotechnology’s protocol. In brief, 10
 
7
 
 cells were treated for 10 min with 1%
formaldehyde to cross-link DNA binding proteins to the DNA and were lysed
in SDS-containing buffer. Cell extracts were sonicated to sheer DNA to 
 
 
 
500
bp and immunoprecipitated overnight with Ab specific for acetylated histone
H4 (Upstate Biotechnology). The recovered protein–nucleic acid complexes
were incubated for 4 h with 0.4 M sodium chloride at 65
 
 
 
C to reverse cross-
links. Purified DNA fragments were amplified 30 cycles using PCR and ana-
lyzed on 1.5% agarose gels. Immunoprecipitations with normal rabbit serum
served as a negative control and PCR for the proximal promoter of the mouse
hypoxanthine guanine phosphoribosyl transferase (HPRT) gene was used as an
internal control. The primers used for the IL-10 promoter were 5
 
 
 
-GGCAC-
CAGAACTCTCCTCTG-3
 
 
 
 and 5 -TGGGTTGAACGTCCGATATT-3 
and for the HPRT promoter were 5 -CTGCCTCTGCCTCCTAAATG-3 
and 5 -CTCCCAGAGGATTCCCAGAT-3 .
In vitro antigen-specific CD4  T cell priming. CD4  T cells were
enriched from total splenocytes of DO11.10 TCR transgenic mice using
anti-CD4 magnetic beads (Miltenyi Biotec). BM-DCs from BALB/c WT
and IL-10 /  mice were matured by LPS with or without IL-4 for 6 h and
extensively washed before adding to enriched CD4  T cells with 0.01  M
OVA323-339 peptide (Peptides International) and 50 U/ml human rIL-2. After
5 d, cells were restimulated with plate-bound anti-CD3 (145-2C11) antibody
overnight. ELISA was performed to detect IFN-  and IL-4 production.
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